Splitting liquor and biotech under a holding company (2002)

Putting two different currents into two different companies

At the core of this split is the judgment to re-house two currents of different character — liquor and biotech — in separate companies. Keep the stable earnings of mature liquor and a biotech business that spends first to buy growth inside one entity, measured on the same ruler, and both readings blur. The idea of giving each business its own management and its own dialogue with the capital markets can be read as the choice of a company that had spent half a century since the central laboratory of 1970 raising a second pillar, and now wanted that pillar to stand on its own. The moment when pandemic PCR demand lifted the whole group’s results is one instance of the arrangement working as designed.

That said, the judgment to put the two into separate companies also created a problem that has outlasted twenty years. Takara Bio, sent out as a listed subsidiary, found the terms of parent-subsidiary listing re-examined as the special demand receded, and in 2026 was taken back into the fold through a tender offer. Reorganizing a business by carving it out and making it independent is a source of funding power in the growing years, and in the stagnant years it summons a different question: how to deal with the capital tied up and the listed subsidiary held. What Takara Holdings faces now is how to fold up, in its next form, the two-business arrangement it chose for itself a quarter of a century ago.